Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women

NCT02059499 is registered in ClinicalTrials.gov with AIDS Malignancy Consortium as lead sponsor.

NCT NCT02059499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02059499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
Lead sponsor
AIDS Malignancy Consortium
Phase
Phase 3
Overall status
Completed
Start date
December 28, 2015
Completion date
May 2, 2024
Enrollment
91 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

anal intraepithelial neoplasia, high-grade squamous intraepithelial lesion, hiv infection